5 Ways That SelexION Technology Will Address Your Biggest Analytical Challenges

Oct 3, 2017 | Blogs, Technology | 0 comments

If you are a scientist working with complex assays, finding a way to significantly improve selectivity of detection could solve some of your biggest analytical headaches. Are we right? If so, then you are in the right place.

If you are confronted with assay selectivity challenges, then explore the SelexION® Differential Mobility Spectrometry (DMS) technology.  SelexION technology delivers analyte separation that is orthogonal to mass separation, helping you to achieve a more selective MS assay, without returning to method development and complex sample preparation strategies.

If this is the first time you have read about the SelexION device, we suggest you also read the previous blog in this series where we introduced the ‘Science Behind SelexION DMS Technology’. Before you click on the link, keep reading to find out the top five ways that SelexION addresses your biggest analytical challenges.  

  1. Detection Challenges due to Matrix Interferences? SelexION technology can separate analyte ions from overlapping matrix interferences within complex samples, allowing for more selective detection of your compound of interest and worry-free quantitation.
  2. Inability to Confidently Separate Isobaric and Isomeric Species? SelexION technology addresses isobaric interferences by separating your sample prior to MS analysis to improve identification, such as separating phospholipid samples into sub-classes for accurate lipid class quantitation or identifying differentially localized modifications on the same peptide sequence.
  3. Quantitation Limits Hindered by High Background Noise? SelexION technology can reduce or remove background noise signal using the separation power of DMS, allowing your compound of interest to be detected at lower levels than previously possible.
  4. Lengthy Sample Preparation Procedures? If you’re required to perform lengthy and complex sample preparation procedures and HPLC conditions to separate your analyte of interest from interfering sample matrix components, simplify your prep procedures and rely on DMS orthogonal separation to reduce background and isolate your compound of interest prior to MS detection.
  5. Looking to Increase Assay Diversity without Decreasing Throughput? Unlike other differential ion mobility approaches, the SelexION DMS device is not permanent. It takes less than 2 minutes to install without breaking vacuum on your system. This means you can use SelexION for your challenging assays, and remove it when it’s not required with minimal impact to your instrument uptime.

Overcome these five common challenges and achieve a new dimension in selectivity by incorporating SelexION DMS separation on your SCIEX Triple Quad™, QTRAP®, or TripleTOF® System.

Overcoming uncertainty in your PFAS analysis

Just like gum on the bottom of a shoe, the existence of per- and poly-fluorinated alkyl substances (PFAS) in our environment is a sticky one. If you’re in the field of environmental testing, then you’re all too familiar with the threat these substances have on public health. While we have learned a lot about them over the years, there is still much more to understand. With the right detection methods, we can gather the information we need to empower us to make informed decisions on reducing the risks they impose.

6 Signs it’s time for a new vendor

A lab’s success depends on many factors from instrument quality to efficient operations, including being partnered with the right vendor. A vendor is more than just a supplier. They should provide you with a high-level quality of support in maximizing the lifespan and performance of your systems, reducing downtime, enhancing ROI and more. How do you know if you’re partnered with the right one? Here are six signs it might be time to find someone new.

Plasmid manufacturing: Setting up your CGT programs for success

Plasmid DNA serves a variety of purposes, from critical starting material for proteins, mRNA, viral vectors, and drug substances. Below, Dr. Emma Bjorgum, the Vice President of Client Services of the DNA Business Unit at Aldevron and an expert in plasmid manufacturing, provided insights into the process and an outlook on the future.

Posted by

0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial